|Type||Public (SIX: EVE) |
|Industry||Biotech Pharmaceutical industry|
|Headquarters||Reinach, Basel-Country, Switzerland|
|Key people||Neil Goldsmith, CEO. Jakob Dynnes Hansen, CFO|
|Products||Natural flavors, sweeteners, and functional ingredients for health, nutrition & wellness products.|
|Revenue||2012 CHF 7M/USD 7.7M|
Evolva is a biotechnology company developing a new, broader range of sustainably produced natural flavors, sweeteners, and functional ingredients for food, beverage, and healthcare products. The company operates primarily in a business-to-business environment, with technology innovation and optimisation responsibilities falling under Evolva’s responsibilities, and scale-up and commercialisation handled by its global partners. The company is headquartered in Reinach, near Basel, Switzerland and has operations in Switzerland, Denmark, India and the United States.
Technology and product portfolio
Evolva leverages its discovery science and proprietary yeast-based fermentation platform to advance the development of natural flavors, sweeteners, and functional ingredients for food, beverage, and healthcare products. The company is focusing initially on high-demand ingredients like vanilla/vanillin, stevia, and saffron. Vanillin and stevia are being co-developed with large, experienced corporate partners. The company currently has one product on the market—fermentation-produced resveratrol, which was approved by European regulators.  This natural compound is produced in grapes and other plants as a response against environmental stress factors. It occurs in red wine, but at low concentrations. Scientific research has shown it to have protective benefits against some health conditions related to aging.
Evolva’s technology originates from the U.S. company Phytera. The technology was incubated in Denmark before the company was established in Switzerland in 2004. The company quickly expanded its activities by opening or acquiring subsidiaries in Denmark and India (2005) and in the United States (2007). In 2009, Evolva became a public company by merging with Arpida Ltd. to create Evolva Holding SA, listed on the Swiss Stock Exchange under the ticker symbol “EVE”  On April 5, 2011 Evolva announced its plans to acquire its R&D partner Abunda Nutrition, Inc., expanding its interests in the development of next-generation nutritional ingredients.
- "Evolva webpage: About Us>Mission & Strategy".
- "Evolva webpage: Partnering".
- "Evolva webpage: Contact & Careers>Contact Details".
- "Evolva webpage: Technology".
- "Evolva webpage: Products> Stevia".
- "Evolva webpage: Products>Resveratrol".
- "Website of Oregon State University - David Sinclair".
- "Harvard Medical School’s interview". Science Friday.
- "Swiss Biotech Report 2010". Swiss Biotech.
- "Evolva announces Abunda acquisition".